Results 141 to 150 of about 4,378 (208)

NTRK1-rearranged histiocytosis: clinicopathologic and molecular features. [PDF]

Blood Adv
Fragneau R, Fraitag S, Kemps PG, Hélias-Rodzewicz Z, Roy S, Bonsang B, Bartlett AL, Dhar S, Jankofsky M, Zlocha J, Svojgr K, Krsková L, de Vries ACH, Verdijk RM, van Laar JAM, Leguit RJ, Drabent P, Carlsen ED, Ho J, Karunamurthy AD, Santi M, Jullié ML, Babor F, Lorsbach R, van Halteren AGS, Héritier S, Diamond EL, Durham BH, Kumar AR, Bhattacharya A, Haroche J, Donadieu J, Borkhardt A, Picarsic JL, Emile JF.   +34 more
europepmc   +1 more source

A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. [PDF]

Future Oncol
Waguespack SG, Cabanillas ME, Bernard-Gauthier V, Assar N, Bloom G, Esparza R, Brose MS.   +6 more
europepmc   +1 more source

NGF/BDNF-Trk/p75NTR signaling in osteosarcoma immunity: biomarkers and therapeutic opportunities. [PDF]

Front Immunol
An L, Zhuang Y, Sun H.
europepmc   +1 more source

Entrectinib-Induced Pericarditis with Cardiac Tamponade in a Patient with Neurotrophic Tropomyosin Receptor Kinase 1 Fusion-Positive Breast Cancer. [PDF]

Case Rep Oncol
Aoyama A, Yoshitomi Y, Shimomura A, Kawamura Y, Taniyama T, Kurozumi A, Kubota S, Hiroi Y, Shimizu C.   +8 more
europepmc   +1 more source

72P Efficacy and safety of larotrectinib as first-line treatment for adult patients with TRK fusion cancer

ESMO Open
M. Casanova, A. Drilon, R. McDermott, A. Italiano, M. Tahara, M. Brose, J.J. Lin, D. Burcoveanu, N. Neu, C. Mussi, L. Shen, D. Hong   +11 more
semanticscholar   +1 more source

The present and future of precision oncology and tumor-agnostic therapeutic approaches. [PDF]

Oncologist
Shah NM, Meric-Bernstam F.
europepmc   +1 more source

Molecular structure for Erbitux and Larotrectinib.

Maria Fazal (21688880), Salma Kanwal (17276643), Muhammad Taskeen Raza (21688883), Asima Razzaque (20521431)   +3 more
openalex   +1 more source

Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center. [PDF]

J Cancer Res Clin Oncol
Rordorf T, Balermpas P, Brezina T, Broglie MA, Freiberger SN, Ikenberg K, Lorch A, Morand GB, Mueller SA, Zoche M, Beyer J, Rupp NJ.   +11 more
europepmc   +1 more source

Precision medicine advances in pancreatic cancer driven by genomic and molecular alterations. [PDF]

World J Gastrointest Oncol
Li X, Jiao Y, Liu YH.
europepmc   +1 more source

Circulating tumor DNA in patients with cancer: insights from clinical laboratory. [PDF]

Adv Lab Med
Illana FJ, Fernández-Galán E, Muñoz-Bravo JL, Valiña Amado L, García Martín C, González-Fernández C, Miró-Cañís S, Trapé J, Martínez-Peinado A, Filella X, González A, Sánchez AB, Díaz-Lagares A, Commission on Biological Markers of Cancer of the Spanish Society of Laboratory Medicine.   +13 more
europepmc   +1 more source